以分子靶向药物为主要研究领域，开展小分子靶向抗肿瘤药物和自身免疫性疾病治疗药物等新药研发工作；在此基础上，进行PROTAC分子的设计、合成和活性评价，探索PROTAC技术在各种疾病中的应用；同时，针对肿瘤组织的特殊性，开展抗肿瘤药物的靶向递送和释放技术研究，提高疗效和安全性。

1. Wu, D.#; Hao, M.#; Dong, S.#; Zhou, W.; Xiong, T.; Mao, C.; Wang, B.; Wang, M.*; Lin, S.*; Jin, J.*; Xu, H.* Discovery and optimization of 4-methylquinazoline derivatives as highly selective PI3Kδ inhibitors for the treatment of acute lung injury. J. Med. Chem. 2026, DOI: 10.1021/acs.jmedchem.6c00288. (# Co-First Authors)
2. Peng, S.; Zhang, Q.; Tian, H.; Zhang, J.; Deng, J.; Qi, H.; Wu, D.; Du, T.; Zhang, K.; Ge, J.; Sheng, L.; Lin, S.*; Ji, M.*; Xu, H.* Discovery and optimization of potent PROTAC degraders of phosphoinositide 3-kinase with significant in vivo anticancer efficacy. J. Med. Chem. 2025, 68, 12800-12818.
3. Lin, S.#; Xiang, N.#; Liu, W.#; Wu, D.#; Chen, Y.#; Xiong, T.; Ge, J.; Zhou, W.; Tian, H.; Zhang, K.; Sheng, L.*; Jin, J.*; Wang, H.; Xu, H.* Optimization of thienopyrimidine derivatives as potent and selective PI3Kδ inhibitors for cancer immunotherapy. J. Med. Chem. 2025, 68, 14859-14881. (# Co-First Authors)
4. Xiong, T.#; Yang, H.#; Lin, S.#; Sheng, L.; Ge, J.; Wang, J.*; Xu, H.* Discovery and optimization of novel tricyclic ubiquitin-specific protease 1 inhibitors for the treatment of BRCA-mutated breast cancer. J. Med. Chem. 2025, 68, 25844-25865. (# Co-First Authors)
5. Lin, S.#; Du, T.#; Zhang, J.#; Wu, D.; Tian, H.; Zhang, K.; Jiang, L.; Lu, D.; Sheng, L.; Li, Y.; Ji, M.*; Chen, X.*; Xu, H.* Optimization of benzamide derivatives as potent and orally active tubulin inhibitors targeting the colchicine binding site. J. Med. Chem. 2022, 65, 16372–16391. (# Co-First Authors)
6. Zhang, J.#; Jiang, H.#; Lin, S.#; Wu, D.; Tian, H.; Jiang, L.; Cui, Y.; Jin, J.*; Chen, X.*; Xu, H.* Design and Optimization of Thienopyrimidine derivatives as potent and selective PI3Kδ inhibitors for the treatment of B-cell malignancies. J. Med. Chem. 2022, 65, 8011–8028. (# Co-First Authors；封面文章)
7. Lin, S.#; Jin, J.#; Liu, Y.#; Tian, H.; Zhang, Y.; Fu, R.; Zhang, J.; Wang, M.; Du, T.; Ji, M.; Wu, D.; Zhang, K.; Sheng, L.; Li, Y.; Chen, X.*; Xu, H.* Discovery of 4-methylquinazoline based PI3K inhibitors for the potential treatment of idiopathic pulmonary fibrosis. J. Med. Chem. 2019, 62, 8873-8879. (# Co-First Authors；封面文章)
8. Lin, S.#; Wang, C.#; Ji, M.; Wu, D.; Lv, Y.; Zhang, K.; Dong, Y.; Jin, J.; Chen, J.; Zhang, J.; Sheng, L.; Li, Y.; Chen, X.*; Xu, H.* Discovery and optimization of 2-amino-4-methylquinazoline derivatives as highly potent phosphatidylinositol 3-kinase inhibitors for cancer treatment. J. Med. Chem. 2018, 61, 6087–6109. (# Co-First Authors)
9. Lin, S.#; Wang, C.#; Ji, M.; Wu, D.; Lv, Y.; Sheng, L.; Han, F.; Dong, Y.; Zhang, K.; Yang, Y.; Li, Y,; Chen, X.*; Xu, H.* Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors. Bioorg. Med. Chem. 2018, 26, 637–646. (# Co-First Authors)
10. Lin, S.#; Li, Y.#; Zheng, Y.; Luo, L.; Sun, Q.*; Ge, Z.; Cheng, T.; Li, R.* Design, synthesis and biological evaluation of quinazoline–phosphoramidate mustard conjugates as anticancer drugs. Eur. J. Med. Chem. 2017, 127, 442-458. (# Co-First Authors)